Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 225 of 360 entries
View as:

Study of Irofulven in Combination With Oxaliplatin in Patients With Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT00374660 Org: User:
Start: 06/30/03 End: 04/30/07 Due: 04/30/08

A 3-Part, Open-Label, Drug-Drug Interaction Study of Concomitant Administration of E2609 With Itraconazole, Rifampin, Digoxin, or Donepezil

Phase: N/A Priority: Normal
NCT ID: NCT02055703 Org: User:
Start: 01/31/14 End: 05/31/14 Due: 05/31/15

A Study of ZYC300 Administered With Cyclophosphamide Pre-Dosing

Phase: N/A Priority: Normal
NCT ID: NCT00381173 Org: User:
Start: 11/30/06 End: 10/31/08 Due: 10/31/09

A Study to Evaluate Next-Dose Transition From Zolpidem to Lemborexant (LEM) for the Treatment of Insomnia

Phase: N/A Priority: Normal
NCT ID: NCT04009577 Org: User:
Start: 07/15/19 End: 06/26/20 Due: 06/26/21

A Study in Subjects With Recurrent Malignant Glioma

Phase: N/A Priority: Normal
NCT ID: NCT01137604 Org: User:
Start: 11/09/10 End: 10/28/14 Due: 10/28/15

Effects of Combination Therapy With Alpha-1 Blocker (Bunazosin or Doxazosin) in the Treatment of Patients With Mild to Moderate Essential Hypertension

Phase: N/A Priority: Normal
NCT ID: NCT00130156 Org: User:
Start: 10/31/05 End: 03/31/09 Due: 03/31/10

Post-marketing Study of Monteplase ("Cleactor") in Patients With Acute Pulmonary Embolism

Phase: N/A Priority: Normal
NCT ID: NCT00442234 Org: User:
Start: 05/01/07 End: 04/01/08 Due: 04/01/09

Single and Multiple Dose Asian Bridging Study

Phase: N/A Priority: Normal
NCT ID: NCT01251731 Org: User:
Start: 07/31/10 End: - Due: -

An Evaluation of the Efficacy and Safety of E2007 in Patients With Painful Diabetic Neuropathy

Phase: N/A Priority: Normal
NCT ID: NCT00505284 Org: User:
Start: 06/30/07 End: 07/31/08 Due: 07/31/09

Trial to Evaluate Safety and Efficacy of Treatment of Physician Choice (TPC) Following First-Line Treatment of Lenvatinib in Subjects With Unresectable Hepatocellular Carcinoma (uHCC)

Phase: N/A Priority: Normal
NCT ID: NCT03433703 Org: User:
Start: 04/26/18 End: 01/07/19 Due: 01/07/20

Trial to Assess Safety and Efficacy of Lenvatinib (18 mg vs. 14 mg) in Combination With Everolimus in Participants With Renal Cell Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT03173560 Org: User:
Start: 08/17/17 End: 06/20/24 Due: 06/20/25

Study to Assess Pharmacokinetic Drug-Drug Interaction Between Avatrombopag When Co-Administered With Fluconazole, Itraconazole, or Rifampin in Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT02809768 Org: User:
Start: 04/30/16 End: 09/30/16 Due: 09/30/17

Compassionate Use of Eribulin for the Treatment of Advanced Breast Cancer Refractory to All Other Marketed Therapies

Phase: N/A Priority: Normal
NCT ID: NCT01142661 Org: User:
Start: 08/31/10 End: - Due: -

E7050 in Combination With Cisplatin and Capecitabine Versus Cisplatin and Capecitabine Alone in Patients With Advanced or Metastatic Solid Tumors and Previously Untreated Gastric Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01355302 Org: User:
Start: 11/30/11 End: 07/31/13 Due: 07/31/14

A Study of ONTAK and CHOP in Newly Diagnosed, Peripheral T-Cell Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT00211185 Org: User:
Start: 03/14/04 End: 12/23/09 Due: 12/23/10

A Study of Eritoran (E5564) Administered IV Over 14 Days Prior to and During Bone Marrow Engraftment in BMT Patients Who Have Received Myeloablative Conditioning Treatment and Are Receiving Bone Marrow or Stem Cells From Matched Related Donors

Phase: N/A Priority: Normal
NCT ID: NCT00756912 Org: User:
Start: 09/30/08 End: - Due: -

Pharmacokinetic Properties of Lorcaserin in Subjects With Renal Impairment

Phase: N/A Priority: Normal
NCT ID: NCT00828438 Org: User:
Start: 10/31/08 End: 02/28/09 Due: 02/28/10

Access Program With Denileukin Diftitox for the Treatment of Patients Currently Receiving Treatment With Commercially Available (Ontak)

Phase: N/A Priority: Normal
NCT ID: NCT01432483 Org: User:
Start: - End: - Due: -

Safety and Tolerability of E5555 and Its Effects on Markers of Intravascular Inflammation in Subjects With Coronary Artery Disease

Phase: N/A Priority: Normal
NCT ID: NCT00312052 Org: User:
Start: 09/30/07 End: 08/31/09 Due: 08/31/10

An Study to Determine the Bioavailability of E2609 Tablets Compared to Capsules and the Effect of Food on Absorption

Phase: N/A Priority: Normal
NCT ID: NCT01716897 Org: User:
Start: 10/31/12 End: 02/28/13 Due: 02/28/14

Study of Perampanel as Adjunctive Treatment for Inadequately Controlled Seizures Associated With Lennox-Gastaut Syndrome

Phase: N/A Priority: Normal
NCT ID: NCT02834793 Org: User:
Start: 12/13/16 End: 07/19/21 Due: 07/19/22

Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E6742 in Healthy Adult Subjects

Phase: N/A Priority: Normal
NCT ID: NCT03082235 Org: User:
Start: 03/03/17 End: 10/11/17 Due: 10/11/18

A Open-label, Three-period, Partial-replicate Design Study to Evaluate the Inter- and Intrasubject Variability of the Avatrombopag To-be-marketed Formulation Administered as Single Doses of 40 mg to Healthy Subjects Receiving a Low-fat Meal

Phase: N/A Priority: Normal
NCT ID: NCT01759394 Org: User:
Start: 10/31/12 End: 03/31/13 Due: 03/31/14

An Extended Access Program (EAP) for Perampanel

Phase: N/A Priority: Normal
NCT ID: NCT02307578 Org: User:
Start: - End: - Due: -

Phase 1 Study to Determine the Effect of Lenvatinib (E7080) on the Pharmacokinetics of Midazolam in Subjects With Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT02686164 Org: User:
Start: 04/18/16 End: 08/16/18 Due: 08/16/19